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Abstract
Background: Nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency is caused by mutations
in the active 21-hydroxylase gene (CYP21A2). The clinical symptoms can vary greatly. To date, no systematic studies
have been undertaken in Germany.
Aims: Description of the phenotype, evaluation of the diagnostics and genotype-phenotype correlation
Patients and methodology: Retrospective analysis of the data of 134 patients (age range 0.1–18.6 years) in a multicentre
study covering 10 paediatric endocrinology centres in Bavaria and Baden-Württemberg. The data was gathered on site from
the medical records. Two hundred and thirty-three alleles with a mutation of the CYP21A2 gene were identified in 126
patients. A genotype-phenotype correlation of the mutation findings was undertaken (C1, severe/mild; C2, mild/mild).
Individuals with a heterozygous mutation of the CYP21A2 were also included (C3). The data was collected with the approval
of the ethics committee of the University Hospital of Erlangen during the period of 2014 and 2015.
Results (MW ± SD): One hundred and seventeen out of 134 patients (115 f, 29 m) were symptomatic. The chronological
age (CA) at diagnosis was 7.1 ± 4.4 years. The most frequent symptom (73.5%) was premature pubarche. The height-SDS on
diagnosis was 0.8 ± 1.3 and the BMI-SDS was 0.8 ± 1.2. Bone age (BA) was ascertained in 82.9% of the symptomatic patients.
The difference between BA and CA was 1.9 ± 1.4 years. Basal 17OHP concentrations were 14.5 ± 19.1 ng/ml (18 patients < 2
ng/ml). In total, 58.1% mild and 34.7% severe mutations were found. The most common mutation was p.Val281Leu (39.1%);
65.8% of the patients could be allocated to group C1. No phenotypical differences were found between the 3 mutation
groups. The 17OHP levels (basal and after ACTH) in the standard ACTH stimulation test were highest in group C1 and also
significantly higher in group C2 as in C3, the ACTH-stimulated cortisol levels (ng/ml) were significantly lower in groups C1
(192.1 ± 62.5) and C2 (218 ± 50) than in C3 (297.3 ± 98.7).
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Conclusion: Most of the patients have symptoms of mild androgenisation. Male patients are underdiagnosed.
Diagnostics are not standardised. Differences between the types of mutations are found in the hormone
concentrations but not in phenotype. We speculate that further, as yet not clearly defined, factors are responsible for
the development of the respective phenotypes.
Keywords: CYP21A2 mutations, 21-Hydroxylase deficiency, Androgenisation, Premature pubarche, 17OHP, ACTH
stimulation test
Background
Nonclassical congenital adrenal hyperplasia due to 21-
hydroxylase deficiency (NC-CAH) is caused by muta-
tions in the active 21-hydroxylase gene (CYP21A2) and
is the most common congenital disorder of steroid bio-
synthesis of the adrenal gland, with an estimated preva-
lence of 1:200–1:1000 in the Caucasian population [1, 2].
The mutations which result in classic congenital adrenal
hyperplasia (CAH) or NC-CAH are classified inter-
nationally according to the residual activity of 21-
hydroxylase in the mutation groups 0, A, B and C [3–5].
Severe mutations are found in groups 0, A and B while
the patients with NC-CAH belong to mutation group C.
Most patients are compound heterozygous, i.e. the geno-
type comprises a combination of mutations, which result
in a mild reduction in enzyme activity on one allele and
of mutations causing either a total (0% residual activity),
a serious (about 2–5% residual activity) or a mild (20–
60% residual activity) reduction in enzyme activity on
the other alleles [4, 6]. The phenotype is influenced by
the activity of the less affected allele, and the residual ac-
tivity of 21-hydroxylase in the patients is around 20–
50% [7]. However, the phenotypical degree of severity
within a genotype can vary greatly and different pheno-
types can be associated with the same mutation [8].
To date, there are no systematic studies for children
with NC-CAH in Germany, and numbers on prevalence
are also lacking. At the bi-annual meeting of paediatric
endocrinologists in Bavaria and Baden-Württemberg, it
was decided to analyse data of affected children in order
to answer questions regarding clinical presentation, la-
boratory and molecular genetic diagnostics and the cor-
relation of genotype to phenotype.
Patients and methods
The study included 134 children and adolescents (age
range 0.1–18.6 years) born between 1972 and 2014
who are treated in 10 different paediatric endocrin-
ology centres in Bavaria and Baden-Württemberg.
The study was planned during the bi-annual meeting
of paediatric endocrinologists in Ulm. The data was
collected retrospectively in the participating hospitals
by one person (N.Sch.) in 2014 and 2015, or the data
was entered into an Excel table in those centres with
few patients.
The height and the body mass index (BMI) of the
patients were calculated in standard deviation scores
(SDS) in accordance with the reference values of
Kromeyer-Hauschild et al. [9]. An SDS value specifies
the difference of a measured value to the mean value
of the reference population of the same age and is
calculated from the difference of the measured value
(actual value) and the mean value (nominal value) di-
vided by the corresponding standard deviation of the
mean value. Bone age (X-ray of the left hand) was
evaluated according to the Greulich and Pyle Atlas
method [10]. Pubarche before the 8th birthday in girls
and before the 9th birthday in boys was assessed as
premature pubarche.
The serum concentrations of 17-hydroxyprogesterone
(17-OHP) and cortisol were measured in the individual
centres according to the directive of the German Med-
ical Association for the Quality Assurance of Laboratory
Medical Examinations (Rili-BÄK). The blood samples
were taken in the morning and in the early follicular
phase in girls who were menstruating. A standard
ACTH stimulation test was carried out on 83 patients
(i.v. 250 μg, blood samples taken at 0 and 60min) and
17-OHP and cortisol were measured. The following are
conversion factors for conventional units to SI units:
17OHP, ng/ml × 3 = nmol/l; cortisol, ng/ml × 2.76 =
nmol/l.
The molecular genetic diagnostics with complete se-
quencing of the CYP21A2 gene, and additionally with
different methods (MLPA, semi-quantitative PCR) an
analysis of the number of copies of the CYP21A2
gene in comparison with the pseudogene CYP21A1P,
was performed in different molecular genetic labora-
tories. Results of the molecular genetic analysis of
126 patients were available. The patients were divided
into three groups according to the number of allele
combinations of the CYP21A2 gene which were
found. Group C1 is compound heterozygous patients
with a severe mutation on one allele (mutations from
groups 0, A or B) and a mild mutation on the other
allele (mutation from group C), group C2 is patients
with a mild mutation (heterozygous or homozygous)
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on both alleles (mutation from group C) and group
C3 is heterozygous individuals with only a mild het-
erozygous mutation on one allele.
Statistics
All statistical analyses were performed using SPSS 23.0
software (IBM Inc., USA), Quantitative data are pre-
sented as the mean ± SD. Normality of the sample was
examined by the Shapiro-Wilk test. Changes in clinical
and laboratory variables between the different mutation
groups were analysed using one-way ANOVA, followed
by the post hoc comparisons using Tukey’s test. Statis-




The diagnosis was made in 134 patients (105 f, 29 m) at
a mean age of 7.1 ± 4.4 (SD) years. Most of the children
were diagnosed between the ages of 6 and 10 years
(Table 1). 78.4% of patients were female; the ratio of fe-
male to male was 3.6:1. One hundred and seventeen pa-
tients (97 f, 20 m) presented to outpatients‘ clinics with
a variety of clinical symptoms, while 17 (8 f, 7 m) did
not yet have any symptoms at the time the data was col-
lected. In these cases, the diagnosis was made in the
process of prenatal diagnostics (n = 4), in CAH newborn
screening (n = 6) and during examination of family
members with affected siblings (n = 7).
Premature pubarche was the most frequent symptom
found in the symptomatic patients with 73.5%, followed
by acne 22.2%, clitoris hypertrophy 19.5%, hirsutism
14.4% and seborrhoea 10.3%. It must be borne in mind
that some symptoms did not present in isolation but also
in different combinations with other symptoms. The
average time from the start of symptoms to diagnosis
was more than 1 year. At the time of diagnosis, the mean
height-SDS was 0.8 ± 1.3 (SD) and the BMI-SDS was 0.8
± 1.2 (SD). Bone age was determined in 97/117 patients
and was, on average, 9.3 ± 3.7 (SD) years. The difference
between bone age and chronological age was on average
1.9 ± 1.4 (SD) years. Bone age was accelerated in 70 pa-
tients (72.2%) > 1 year.
Laboratory diagnostics
On the first visit, the mean basal 17OHP concentrations
(n = 130) were 14.5 ± 19.1 (SD) ng/ml (range, 0.3-112).
No significant differences between the different age
groups were seen either for the basal or for the stimu-
lated 17-OHP (Fig. 1). The basal 17OHP levels were < 2
ng/ml in 18 patients and > 2 ng/ml in 112 patients. In
the ACTH test (n = 83), the 17OHP concentrations in-
creased from an average of 18.8 ± 24.3 (SD) to 61.1 ±
79.9 (SD) ng/ml after 60 min. In 13 patients with a basal
17OHP < 2 ng/ml, the ACTH-stimulated 17OHP levels
were > 10 ng/ml in 5 patients, whereas the levels did not
increase in 8 patients.
Cortisol levels (ng/ml) were measured in the ACTH
test in 74 patients and could be stimulated from mean
127.2 ± 57.2 (SD) to 225.9 ± 79.1 (SD). After ACTH
stimulation, 20 patients had maximal cortisol levels of <
180 ng/ml (< 500 nmol/L).
Molecular analysis
We identified 233 alleles with a mutation in the
CYP21A2 gene in 126 patients. Of these, about 58% be-
long to the group with mild mutations and 34.7% to the
severe mutations. The point mutation p.Val281Leu was
found most frequently in the mild mutations (39.1%),
followed by p.Pro453Ser (8.2%) and p.Pro30Leu (6.9%)
mutations. A deletion of the CYP21A2 gene was most
frequent among the severe mutations (11.1%), followed
by the p.Ile172Asn mutation (6.9%), small gene conver-
sions (6.0%) and the c.290-13A/C>G mutation (5.2%).
There was a deletion of the pseudogene CYP21A1P on
five alleles (2.1%). The mutation p.Gln318X in combin-
ation with a heterozygous duplication of the CYP21A2
gene was found on two alleles (0.9%).
Most of the patients (65.8%) were compound heterozy-
gous with both a severe and a mild mutation, and they
were assigned to group C1. In group C2, there were 21
Table 1 Age distribution of the patients at diagnosis
Group Number %
0–1 year 16 11.9
1–6 years 27 20.1
6–10 years 66 49.3
> 10 years 25 18.7
Total 134 100.0
Fig. 1 Serum concentrations of 17OHP (ng/ml; logarithmic scale) in
the ACTH test (0, 60 min) in relation to the different age groups
(years); 0–1 (n = 5), 1–6 (n = 18), and 6–10 (n = 43), > 10 (n = 17);
black dotted line, median; conversion factor to SI, ng/ml × 3
= nmol/l
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patients, each with mild mutations (heterozygous: n =
11, homozygous: n = 10) on both alleles (16.6%). Only
one mutation was found in 17 individuals (13.4%) (group
C3). Patients with deletions of the pseudogene and with
a duplication of the CYP21A2 gene were not included.
Genotype-phenotype correlation
As shown in Table 2, group C1 comprised 83 patients
(63 f, 20 m) with both a severe and a mild mutation of
the CYPA2-gene. Of these, 71 patients (85.5%) were
symptomatic. Group C2 comprised 21 patients (19 f, 2
m) with two mild mutations. In this group, all patients
except one boy were symptomatic (95.2%). Group C3
encompassed the individuals (13 f, 4 m) with a heterozy-
gous CYP21A2 gene mutation. Here, too, 94.1% (16/17)
were symptomatic.
Premature pubarche was the most frequent symptom in
all three mutation groups. No significant phenotypical differ-
ences were found between the three mutation groups; how-
ever, marked differences were seen in the hormone levels.
The basal 17-OHP concentrations in group C1 were signifi-
cantly higher than in C2 (p < 0.001) and C3 (p < 0.001). The
difference between C2 and C3 was also significant (p
< 0.05). After ACTH the stimulated 17-OHP in
groups C1 and C2 were significantly greater than in
C3 (p < 0.01); no such differences were found be-
tween C2 and C3 (Fig. 2). No difference was seen in
basal cortisol levels between the 3 groups. After
ACTH stimulation, the maximal cortisol level in the
groups C1 and C2 was significantly lower than in C3
(p < 0.01), while no differences were found between
groups C1 and C2. Insufficient cortisol reserves (max.
cortisol < 180 ng/ml) were seen in 20 patients (C1: n
= 18; C2: n = 2).
Discussion
Classic CAH occurs in two clinical forms, a form with
salt wasting and a simple virilising form without aldos-
terone deficiency [11–13], whereas, as a rule, only symp-
toms of increased androgen production are seen in NC-
CAH [14, 15]. The clinical symptoms vary greatly. When
the symptoms are less pronounced, many patients, and
particularly the boys, will be diagnosed only by chance
or not at all [2, 16]. In almost all published studies, the
Table 2 Demographic and clinical characteristics of the mutation groups C1, C2 and C3; mean ± standard deviation (SD);
conversion factors: 17OHP ng/ml × 3 = nmol/L, cortisol ng/ml × 27.6 = nmol/L
Groups C1 C2 C3 p
Mutations severe/mild mild/mild heterozygous
Number of patients/individuals (n) 83 21 17
Sex (f/m) 63/20 19/2 13/4
Chronological age (CA) at diagnosis (years) 6.9 ± 4.3 6.2 ± 3.3 9.0 ± 5.1 ns
Symptomatic [n (%)] 71 (85.5) 20 (95.2) 16 (94.1) ns
Symptoms (%)
Premature pubarche 73.2 85.0 68.8 ns
Acne 23.9 30.0 18.8 ns
Clitoris hypertrophy* 17.2 15.7 12.5 ns
Hirsutism* 9.5 5.2 3.1 < 0.01 a
Seborrhoea 9.9 5.0 18.8 < 0.05 c
Height (SDS) 0.8 ± 1.3 1.1 ± 1.3 0.2 ± 1.3 ns
Bone Age (BA) > 1 year (%) 73.3 84.2 80.0 ns
Delta BA-CA (years) 2.0 ± 1.5 1.9 ± 1.4 1.8 ± 1.0 ns
17OHP (ng/ml) 19.5 ± 22.4 9.4 ± 7.4 4.1 ± 6.6 < 0.01a,b
< 0.05c
ACTH test (n) 46 14 13
17OHP (ng/ml) 0 min 27.3 ± 28.8 12.7 ± 11.1 2.7 ± 2.6 < 0.01a,b,c
17OHP after ACTH 83.7 ± 97.4 58.7 ± 37.3 9.0 ± 4.2 < 0.001a,c
Cortisol (ng/ml) 0 min 119.4 ± 53.0 134.9 ± 56.8 112.8 ± 69.8 ns
Cortisol after ACTH 192.0 ± 62.5 218.4 ± 50.1 297.3 ± 98.7 < 0.01a,c
ns not significant
*In relation to the number of girls
aSignificant differences between groups C1 and C3
bSignificant differences between groups C1 and C2
cSignificant differences between groups C2 and C3
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number of male patients was markedly smaller than the
number of female patients [6, 17–19]. In our cohort, the
mean age of the patients at diagnosis was 7.1 years and
8.3 years in a comparable study in Turkey [19]. In most
of the studies, the mean age is markedly higher, since
adults were also examined. The most frequently reported
clinical symptom is premature pubarche, with the details
on frequency ranging from 45.3 [19] to 88.3% [18]. If the
symptom is considered in relation to sex, the frequency
of premature pubarche in girls and boys in our cohort
was almost equal, while it was conspicuously more fre-
quent in girls (88.5%) than in boys (28.9%) in the Greek
cohort [18]. At birth, most of the girls with NC-CAH
have unobtrusive external genitalia. However, clitoris
hypertrophy may be noticeable when the diagnosis is
made. The reported frequencies, ranging from 3.1
[19] to 13.4% [20] are lower than in our cohort with
19.5%. The signs of androgenisation increase during
puberty and in adulthood [15, 21]. The numbers on
hirsutism vary between 28.6 and 53% [19, 20]. We are
not able to evaluate the linear growth of the children
since no old growth data were available at the time
of diagnosis. Bone age should also be determined in
children with androgenisation. In our cohort, bone
age was determined in 97 patients, and in 70 (72.2%)
patients, it was > 1 year accelerated. Symptomatic chil-
dren can have increased linear growth and accelerated
bone age [22]; the final height may, however, be re-
duced [23]. Children without clinical symptoms have
normal linear growth [24]. In our cohort, 12.4% and
in the Greek cohort, 14.6% of patients were asymp-
tomatic [18].
The mild mutation p.Val281Leu in Exon 7 is found
most frequently on the alleles, with frequencies lying be-
tween 25 and 50% [16, 18, 19, 25]. In our cohort, this
mutation was found most frequently (39%), followed by
mutations p.Pro453S (Exon 10) and Pro30L (Exon 1).
The most frequent severe mutation in our cohort was
the deletion of the CYP21A2-gene (11.1%), whereas the
Intron 2-mutation IVS2-13A/C>G was seen most fre-
quently in the Greek cohort [18]. Most of the patients
are compound heterozygous for two different mutations
of the CYP21A2-gene on both alleles. In our cohort,
68.5% the patients were compound heterozygous for a
severe (classic) and a mild (non-classic) mutation,
whereas the percentage (severe/mild) range from 50.4%
in the Greek cohort [18] to 12.6% in the Turkish cohort
[19]. The number of our patients with mild mutations
(16.6%) was lower than in the Turkish cohort (34%) and
the portion of heterozygous patients in our study
(13.4%) was also markedly lower than in the Turkish
population, which was 47.8% [19]. The diagnosis was
made by molecular genetic analysis in seven children
during examination of family members with affected sib-
lings at the request of the parents.
The basal 17-OHP concentration in NC-CAH patients
is usually raised [14]. Higher 17OHP levels were found
in the literature in adolescent girls than in children [20],
although we were unable to determine any age differ-
ences. Significantly, higher basal 17-OHP levels were
found in patients with a compound heterozygous muta-
tion (severe/mild) than in patients with two mild muta-
tions [18, 21, 25, 26]. In our cohort, the patients in
group 1 (compound heterozygous mutation: severe/
mild) also had higher basal values, and in the ACTH
test, they also had higher stimulated 17OHP-values than
the patients with two mild mutations (group 2), but the
difference was not statistically significant. Basal 17OHP
levels < 2 ng/ml should rule out NC-CAH [13, 27, 28].
This proposition is not shared by all working groups [18,
21, 29]. In our cohort, 4 (3.8%) out of 101 patients with
a molecular-genetically confirmed NC-CAH (groups 1
and 2) and 6 (2.2%) out of 280 patients in the Greek co-
hort had a basal 17OHP level of < 2 ng/ml [18].
The ACTH stimulation test is regarded as the gold
standard in laboratory diagnostics—also in order to dif-
ferentiate from other non-classic CAH forms with 11β-
hydroxylase- or 3β-hydroxysteroid-dehydrogenase defi-
ciency [2]. In our cohort, the test was performed in only
81 (61.9%) out of 134 patients and in 220 (85.2%) out of
258 patients in the Turkish study. 17OHP levels from >
10 ng/ml after ACTH stimulation are considered a diag-
nosis for NC-CAH [13, 21, 30, 31]. However, in an as-
sessment of women with clinical hyperandrogenism,
only 24% of them with a stimulated 17OHP > 10 ng/ml
had a molecular-genetically confirmed NC-CAH [32]. In
our cohort, all patients with NC-CAH had ACTH-
stimulated 17OHP values > 10 ng/ml, whereas in the
Turkish cohort the percentage was 91.8% [19]. Heterozy-
gous gene carriers can also be identified with the ACTH
Fig. 2 Serum concentrations of 17OHP (ng/ml; logarithmic scale) in
the ACTH test (0, 60 min) in relation to the mutation groups: C1
(severe/mild; n = 46), C2 (mild/mild; n = 14), and C3 (heterozygous;
n = 13); black dotted line, median; conversion factor to SI, ng/ml × 3
= nmol/l
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test, although here there is a greater overlap with the
healthy population [31, 33]. Stimulated 17-OHP levels
between 2 and 10 ng/ml have been reported in heterozy-
gous gene carriers [34]. Our results show that a cut-off
level of 17OHP > 10 ng/ml in the ACTH test does not
definitely distinguish heterozygous gene carriers from
patients. Of the molecular-genetically confirmed hetero-
zygous individuals in our cohort (group C3), five had an
ACTH-stimulated 17OHP level > 10 ng/ml and 8 pa-
tients had levels < 10 ng/ml.
Since most patients have normal cortisol levels
(basal and 60 min after ACTH) and thus react ad-
equately to stress [35–37], measuring cortisol in the
ACTH test is not considered necessary and is not
critically examined. In our cohort, a standard ACTH
test was performed in 83 patients and cortisol was
measured in 73 patients. ACTH-stimulated cortisol
values < 180 ng/ml (< 500 nmol/l) are generally consid-
ered to be pathological and are regarded as dimin-
ished cortisol reserves. A French working group was
able to show that 60% of children with NC-CAH had
diminished cortisol reserves [38]. In our cohort, the
proportion was 27.4%, and in other studies, it is be-
tween 15.4 and 21.5% [19, 39]. To date, no generally
accepted guidelines for therapy in stress situations
have been developed for patients with NC-CAH [40].
Patients with diminished cortisol reserves can only be
detected with an ACTH test and receive adequate
therapy in stress situations [38].
No significant phenotypical differences were found in
a comparison of the three mutation groups. It is remark-
able that heterozygous individuals have the same clinical
symptoms as the patients in groups C1 and C2. It is a
known fact that heterozygous gene carriers have symp-
toms of hyperandrogenism [41]. Women with hyperan-
drogenism are more frequently identified as
heterozygous gene carriers for a non-classic CYP21A2
mutation than in the general population [42, 43], but to
date, there is no precise explanation for the symptoms
described in the heterozygous patients [44].
Conclusion
The clinical symptoms in patients with non-classic
CAH are variable and sometimes only very mild. The
symptoms in the molecular-genetically heterozygous
patients are no different from those in the patients
with compound heterozygous (severe/mild) or homo-
zygous (mild/mild) mutations. We speculate that
many patients, in particular males, have not yet been
diagnosed. This is evidenced by the fact that the
number of patients who are being treated in the cen-
tres involved is lower by a factor of about 5 than the
number of patients with classic CAH with 21-
hydroxylase defect. The clinical and laboratory
diagnostics performed when NC-CAH is suspected
vary in the different centres. The variability in the la-
boratory findings demonstrates that a definitive diag-
nosis can only be confirmed molecular-genetically. It
is therefore imperative that a consensus is reached
among paediatric endocrinologists in relation to diag-
nosis of children with NC-CAH.
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